<!DOCTYPE html>
<!--[if lt IE 9]><html class="no-js lt-ie9" lang="en" dir="ltr"><![endif]-->
<!--[if gt IE 8]><!--><html class="no-js" lang="en" dir="ltr"><!--<![endif]-->
	<head>
		<meta charset="utf-8">
		<!-- Web Experience Toolkit (WET) / Boîte à outils de l'expérience Web (BOEW) wet-boew.github.io/wet-boew/License-en.html / wet-boew.github.io/wet-boew/Licence-fr.html -->
		<title>Medical devices - Find out what health product authorization you need - Canada.ca</title>
		<meta content="width=device-width,initial-scale=1" name="viewport">
		<!-- Meta data -->
		<!-- Meta data-->
		<!-- Load closure template scripts -->
		<script type="text/javascript" src="https://www.canada.ca/etc/designs/canada/cdts/gcweb/v4_0_30/cdts/compiled/soyutils.js"></script>
		<script type="text/javascript" src="https://www.canada.ca/etc/designs/canada/cdts/gcweb/v4_0_30/cdts/compiled/wet-en.js"></script>
		<link href="https://test.canada.ca/covid-19-guidance/proto/css/alpha-beta-banner.css" rel="stylesheet">

		<!-- Write closure template -->
		<script type="text/javascript">
			document.write(wet.builder.refTop({
			}));
		</script>
	</head>
	<body vocab="http://schema.org/" typeof="WebPage">
		<div id="def-top">
		</div>
		<!-- Write closure template -->
		<script type="text/javascript">
			var defTop = document.getElementById("def-top");
			defTop.outerHTML = wet.builder.top({
				lngLinks: [{
					lang: "fr",
					href: "travel-advice-fr.html",
					text: "Français"
				}],
				breadcrumbs: [{
					title: "Home",
					href: "https://www.canada.ca/en.html"
				},{
					title: "Health",
					href: "https://www.canada.ca/en/services/health.html"
				},{
					title: "Diseases and conditions",
					href: "https://www.canada.ca/en/public-health/services/diseases.html"
				},{
					title: "Coronavirus (COVID-19)",
					href: "landing.html"
				}],
				search: true,
				siteMenu: true,
				showPreContent: true
			});
</script>

<main role="main" property="mainContentOfPage" class="container">

	<h1 property="name" id="wb-cont" dir="ltr">
		Drugs and vaccines for COVID-19: Overview <br> </h1>
		<div class="mwsgeneric-base-html parbase section">
		
		
			
			<div class="gc-stp-stp">
				<div class="row">
					<ul class="toc lst-spcd col-md-12">
						<li class="col-md-4 col-sm-6"><a class="list-group-item " href="./drugs-vaccines-progress.html">Progress</a></li>
						<li class="col-md-4 col-sm-6"><a class="list-group-item active" href="">List of authorized clinical trials</a></li>
						<li class="col-md-4 col-sm-6"><a class="list-group-item" href="./drugs-vaccines-regulatory-response.html">Regulatory response</a></li>
						<li class="col-md-4 col-sm-6"><a class="list-group-item" href="./drugs-vaccines-conducting-clinical-trials.html">Conducting a COVID-19 clinical trial</a></li>
					</ul>
				</div>
			</div>
		
		
		</div>
		<div class="mwsgeneric-base-html parbase section">
		
		
			
			<p>The table below lists the COVID-19 drugs, including vaccines, currently being investigated in clinical trials authorized by Health Canada. Authorization is through the <a href="https://laws-lois.justice.gc.ca/eng/regulations/c.r.c.%2C_c._870/page-133.html#h-577812"><em>Food and Drug Regulations</em></a> or the <a href="/en/health-canada/services/drugs-health-products/covid19-industry/interim-order-respecting-clinical-trials-medical-devices-drugs.html">interim order for clinical trials for medical devices and drugs related to COVID-19</a>.</p>
			<p>Health Canada continues to discuss potential clinical trials with a number of sponsors. We will update the list as new trials related to drugs or vaccines for COVID-19 are authorized.</p>
			<table class="wb-tables table table-bordered table-striped table-hover table-responsive small" data-wb-tables="{ &quot;paging&quot;: false }">
			  <thead>
				<tr>
				  <th scope="col">Trial Name /Protocol #/control #</th>
				  <th scope="col">Title</th>
				  <th scope="col">Interventions</th>
				  <th scope="col">Authorization holder</th>
				  <th scope="col">Authorization date</th>
				  <th scope="col">Clinicaltrials.gov Link</th>
				</tr>
			  </thead>
			  <tbody>
				<tr>
				  <td>115769<br>
					(Control #238857)</td>
				  <td>Safety and Efficacy of Post-Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the prevention of Corona Virus Infectious Disease-19 (COVID-19) in high-risk patients/residents in Institutions</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>St. Joseph's Health Care Parkwood site</td>
				  <td>2020-05-09</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>20-5449<br>
					(Control #239579)</td>
				  <td>Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted with COVID-19</td>
				  <td>Treatment: nitric oxide</td>
				  <td>University Health Network</td>
				  <td>2020-06-25</td>
				  <td>NCT04383002</td>
				</tr>
				<tr>
				  <td>2149<br>
					Control # 240138<br>
					Authorized under Clinical Trials Interim Order</td>
				  <td>Sedating with Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters and Survival; Multicentre Open-Label, Pragmatic, Randomised Controlled Trial and a Parallel Prospective (Non-Randomised) Cohort Study</td>
				  <td>Treatment: isoflurane, sevoflurane</td>
				  <td>Sunnybrook Health Sciences Centre</td>
				  <td>2020-06-10</td>
				  <td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04415060?term=NCT04415060&amp;draw=2&amp;rank=1">NCT04415060</a></td>
				</tr>
				<tr>
				  <td>776228483 PROACTIVE<br>
					(Control # 240296)</td>
				  <td>Propranolol as an anxiolytic to reduce the use of sedatives for critically ill adults receiving mechanical ventilation: an open-label randomized controlled trial. (PROACTIVE)</td>
				  <td>Treatment: propranolol</td>
				  <td>Ottawa Hospital Research Institute</td>
				  <td>2020-06-10</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>AB002<br>
					(Control #238815)</td>
				  <td>Multicentre, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of LSALT PEPTIDE as Prevention of Acute Respiratory Distress Syndrome (ARDS) in Patients Infected with SARS-COV-2 (COVID-19)</td>
				  <td>Treatment: LSALT Peptide</td>
				  <td>Arch Biopartners Inc.</td>
				  <td>2020-05-07</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>Ad5-nCoV-2020003<br>
					(Control # 239283)</td>
				  <td>A Randomized, Observer-Blind, Dose-escalation Phase I/II Clinical Trial of Ad5-nCoV Vaccine in Healthy Adults from 18 to &lt;85 years of age in Canada</td>
				  <td>Vaccine: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV)</td>
				  <td>CanSino Biologics Inc.</td>
				  <td>2020-05-15</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>AGN120-3<br>
					(Control #238605)</td>
				  <td>A Randomized Open Label Phase 2/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed COVID-19 Infected Hospitalized Patients.</td>
				  <td>Treatment: NP-120 (Ifenprodil)</td>
				  <td>Algernon Pharmaceuticals</td>
				  <td>2020-04-29</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>BAI_COV19_01<br>
					(Control #239071)</td>
				  <td>Inhaled NO for the treatment of COVID-19 caused by SARS-CoV-2</td>
				  <td>Treatment: nitric oxide</td>
				  <td>Beyond Air. Inc.</td>
				  <td>2020-05-19</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>BHC-RIB 5401-HC<br>
					(Control #238007)</td>
				  <td>An Open Label Study to Evaluate the Safety and Efficacy of Virazole<sup>®</sup>&nbsp;(ribavirin for inhalation solution, USP) in Hospitalized Adult Participants with Respiratory Distress Due to COVID-19</td>
				  <td>Treatment: ribavirin (Virazole<sup>®</sup>)</td>
				  <td>Valeant Canada LP/Valeant Canada S.E.C.</td>
				  <td>2020-04-08</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04356677?term=04356677&amp;draw=2&amp;rank=1">NCT04356677</a></td>
				</tr>
				<tr>
				  <td>CATCO<br>
					2114<br>
					(Control #237108)</td>
				  <td>The Canadian arm of the WHO SOLIDARITY Trial.<br>
					A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients.</td>
				  <td>Treatment: remdesivir, interferon beta-1a</td>
				  <td>Sunnybrook Research Institute</td>
				  <td>2020-03-18</td>
				  <td><a href="https://clinicaltrials.gov/show/NCT04330690">NCT04330690</a></td>
				</tr>
				<tr>
				  <td>CINC424J12301 RUXCOVID<br>
					(Control # 240395)</td>
				  <td>Phase 3 Randomized, double-blind, placebo-controlled, multi-centre study to assess the efficacy and safety of ruxolitinib in Patients with COVID-19 Associated Cytokine Storm (RUXCOVID)</td>
				  <td>Treatment: Jakavi (ruxolitinib)</td>
				  <td>Novartis Pharmaceuticals Canada Inc.</td>
				  <td>2020-06-16</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04362137?term=ruxcovid&amp;cond=covid&amp;draw=2&amp;rank=1">NCT04362137</a></td>
				</tr>
				<tr>
				  <td>CIRCA-19<br>
					(Control # 238608)</td>
				  <td>Cellular Immunotherapy for COVID-19 acute respiratory distress syndrome (ARDS)</td>
				  <td>Treatment: (1) Allogeneic Bone Marrow Mesenchymal Stromal Cells (BM-MSCs) / (2) Allogeneic Umbilical Cord Mesenchymal Stromal Cells (UC-MSC)</td>
				  <td>Ottawa Hospital Research Institute</td>
				  <td>2020-05-15</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td id="cobra">COBRA<br>
					(Control # 238868)</td>
				  <td>A randomized, double-blind, placebo-controlled phase 3 study: Efficacy and safety of recombinant BCG VPM1002 in reducing SARS-CoV-2 infection rate and COVID-19 severity</td>
				  <td>Vaccine: Recombinant<br>
					Mycobacterium bovis<br>
					BCGΔureC::hly</td>
				  <td>Princess Margaret Cancer Centre</td>
				  <td>2020-05-08</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>COLCORONA<br>
					MHIPS-2020-001<br>
					(Control # 237317)</td>
				  <td>Colchicine coronavirus SARS-COV2 trial (COLCORONA)</td>
				  <td>Treatment: colchicine</td>
				  <td>Montreal Heart Institute</td>
				  <td>2020-03-20</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04322682">NCT04322682</a></td>
				</tr>
				<tr>
				  <td>CONCOR-Kids<br>
					(Control # 238820)</td>
				  <td>CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children</td>
				  <td>Treatment: Apheresis frozen plasma from recovered COVID-19 patients (Convalescent Plasma)</td>
				  <td>C17 Council</td>
				  <td>2020-05-04</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>CONTROL-COVID-Favipiravir-1<br>
					(Control #239133)</td>
				  <td>Control of COVID-19 outbreak in long term care</td>
				  <td>Treatment: favipiravir</td>
				  <td>Appili Therapeutics Inc.</td>
				  <td>2020-05-18</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>CORIPREV-1<br>
					(Control # 237350)</td>
				  <td>COVID-19 Ring-Based Prevention Trial with lopinavir/ritonavir (CORIPREV-LR).</td>
				  <td>Treatment: lopinavir/ ritonavir</td>
				  <td>Unity Health Toronto</td>
				  <td>2020-03-21</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04321174?cond=covid&amp;draw=2">NCT04321174</a></td>
				</tr>
				<tr>
				  <td>COVACTA<br>
					(Control #: 237397)</td>
				  <td>A randomised, double-blind, placebo-controlled, multicentre study to evaluate the safety and efficacy of tocilizumab in patients with severe COVID-19 pneumonia.</td>
				  <td>Treatment: Actemra<sup>®</sup>/RoActemra<sup>®</sup><br>
					(tocilizumab)</td>
				  <td>Hoffmann-La Roche Limited</td>
				  <td>2020-03-25</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/record/NCT04320615?cond=covid&amp;draw=2">NCT04320615</a></td>
				</tr>
				<tr>
				  <td>COVID-CTP-01 (Control # 237786)</td>
				  <td>Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating NORS Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers &amp; Individuals at Risk of Infection</td>
				  <td>Treatment: nitric oxide</td>
				  <td>Sanotize Research &amp; Development Corp.</td>
				  <td>2020-04-18</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04337918">NCT04337918</a></td>
				</tr>
				<tr>
				  <td>COVID-CTP-02 (Control #240702)</td>
				  <td>Multi-center, double-blinded placebo-controlled, phase II clinical efficacy study evaluating NORS to treat and prevent the exacerbation of infection in individuals with documented mild COVID-19</td>
				  <td>Treatment: nitric oxide</td>
				  <td>Sanotize Research &amp; Development Corp.</td>
				  <td>2020-06-30</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>COVID19 PEP RCT - Canada<br>
					2020-6549<br>
					(Control # 237355)</td>
				  <td>Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial (COVID19 PEP RCT - Canada)</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>Research Institute of the McGill University Health Centre</td>
				  <td>2020-03-25</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04308668">NCT04308668v</a></td>
				</tr>
				<tr>
				  <td id="CP-PRO-CoVLP-019">CP-PRO-CoVLP-019<br>
					(Control # 240922)</td>
				  <td>A randomized, partially-blinded, dose-ranging phase 1 study to assess the safety, tolerability, and immunogenicity of a recombinant coronavirus-Like particle COVID-19 vaccine in adults 18-55 Years of age</td>
				  <td>Vaccine: Coronavirus-like Particle (CoVLP) COVID-19 Vaccine</td>
				  <td>Medicago Inc.</td>
				  <td>2020-07-09</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>CTSN-MSC-ARDS001<br>
					(Control #241138)</td>
				  <td>Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome</td>
				  <td>Treatment: Remestemcel-L</td>
				  <td>Mesoblast, Inc.</td>
				  <td>2020-07-31</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>D1690C00081<br>
					(Control #240352)<br>
					Authorized under Clinical Trials Interim Order</td>
				  <td>An International, Multicenter, randomized, double-blind, placebo-controlled, Phase III study evaluating the efficacy and safety of dapagliflozin in respiratory failure in patients with COVID-19</td>
				  <td>Treatment: DAPAGLIFLOZIN</td>
				  <td>Saint Luke's Hospital of Kansas City</td>
				  <td>2020-07-04</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>DISCONNECT-1<br>
					CTA Control # 241689</td>
				  <td>DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1): Phase I pilot study investigating the safety and feasibility of inhaled rhDNase1 and its impact on neutrophil extracellular traps (NETs) in non-ventilated COVID-19 infected patients</td>
				  <td>Treatment: Pulmozyme (Dornase Alfa)</td>
				  <td>The Research Institute of the McGill University Health Centre</td>
				  <td>2020-07-24</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04409925?term=McGill+University&amp;cond=Covid19&amp;draw=2&amp;rank=6">NCT04409925</a></td>
				</tr>
				<tr>
				  <td>EB05-04-2020<br>
					(Control #239462)<br>
					CTA issued under CT Interim Order</td>
				  <td>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + Standard of Care (SOC) Vs. Placebo + SOC in Adult Hospitalized Patients with Moderate to Severe COVID-19 Pneumonia</td>
				  <td>Treatment: EB05</td>
				  <td>Edesa Biotech Research Incorporated</td>
				  <td>2020-06-12</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>EXTENDED-P2<br>
					(Control # 240041)</td>
				  <td>EXTENDED (Novel O Therapeutic NaN02 for COVID-19 induced ARDS) Phase IIa Trial</td>
				  <td>Treatment: perflenapent (NaNO2)</td>
				  <td>Research Institute of the McGill University Health Centre</td>
				  <td>2020-06-10</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>GRAAL-2020-01<br>
					(Control # 238201)</td>
				  <td>A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)</td>
				  <td>Treatment: Apheresis frozen plasma from recovered COVID-19 patients (Convalescent Plasma)</td>
				  <td>Hamilton Health Sciences</td>
				  <td>2020-04-16</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04348656?id=NCT04348656&amp;draw=2&amp;rank=1&amp;load=cart">NCT04348656</a></td>
				</tr>
				<tr>
				  <td>GS-US-540-5821<br>
					(Control # 238163)</td>
				  <td>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-COV2 (COV) Infection</td>
				  <td>Treatment: remdesivir</td>
				  <td>Gilead Sciences Canada Inc.</td>
				  <td>2020-04-15</td>
				  <td><a href="https://clinicaltrials.gov/show/NCT04323761">NCT04323761</a></td>
				</tr>
				<tr>
				  <td>HEROS-1<br>
					(Control # 237851)</td>
				  <td>Protecting Frontline Health Care Workers from COVID-19 with hydroxychloroquine Pre-Exposure Prophylaxis: A randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>University Health Network</td>
				  <td>2020-04-03</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04333732?cond=COVID19&amp;cntry=CA&amp;draw=5">NCT04374942</a></td>
				</tr>
				<tr>
				  <td>HOPE<br>
					ABCOV-01(Control # 237739)</td>
				  <td>A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of oral hydroxychloroquine for the treatment of SARS-CoV-2 positive patients for the prevention of severe COVID-19 disease (Short title: ALBERTA HOPE COVID-19)</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>University of Calgary</td>
				  <td>2020-04-09</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04329611">NCT04329611</a></td>
				</tr>
				<tr>
				  <td>IC.8 (Control # 240586) Filed under the Clinical Trial Interim Order</td>
				  <td>COV-IMMUNO - A Randomized, Phase III Trial of Immunization with IMM-101 versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure</td>
				  <td>Vaccine: IMM-101</td>
				  <td>Canadian Cancer Trials Group, Cancer Research Institute, Queen's University</td>
				  <td>2020-06-24</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04442048?term=Canadian+Cancer+Trials+Group&amp;cond=COVID-19&amp;draw=2&amp;rank=1">NCT04442048</a></td>
				</tr>
				<tr>
				  <td>JF-4-2020<br>
					(Control # 238558)</td>
				  <td>Interferon Lambda for Immediate Antiviral therapy at Diagnosis (ILIAD): A phase II randomized, open-label, multicenter, trial to evaluate the effect of peginterferon lambda for the treatment of COVID-19</td>
				  <td>Treatment: Peginterferon Lambda-1A</td>
				  <td>University Health Network</td>
				  <td>2020-04-29</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>LAU-20-01<br>
					(Control #238614)</td>
				  <td>A Double-Blind, Randomized, Placebo-Controlled, Pilot Phase II Study of the Efficacy and Safety of Lau-7B in the Treatment of Adult Hospitalized Patients with COVID-19 Disease</td>
				  <td>Treatment: LAU-7B (Fenretinide)</td>
				  <td>Laurent Pharmaceuticals</td>
				  <td>2020-05-02</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>LESSCOVID<br>
					(Control #238851)</td>
				  <td>Exogenous Surfactant Administration for Patients with COVID-19</td>
				  <td>Treatment: BLES (bovine lipid extract surfactant suspension)</td>
				  <td>St. Joseph's Health Centre London</td>
				  <td>2020-05-05</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04375735?term=Exogenous+Surfactant+Administration+for+Patients+with+COVID-19&amp;draw=2&amp;rank=1#contacts">NCT04375735</a></td>
				</tr>
				<tr>
				  <td>LOVIT-COVID MP-31-2021-3741<br>
					(Control #239705)</td>
				  <td>Lessening Organ Dysfunction with VITamin C - COVID (LOVITCOVID)</td>
				  <td>Treatment: Vitamin C</td>
				  <td>Centre de recherche du centre hospitalier universitaire de Sherbrooke</td>
				  <td>2020-06-05</td>
				  <td>NCT04401150</td>
				</tr>
				<tr>
				  <td>Mild-CONTAIN<br>
					2021-6638<br>
					(Control # 239123)</td>
				  <td>Mild - CONTAIN CiclesOnide cliNical TriAl covId-19 treatmeNt</td>
				  <td>Treatment: Ciclesonide</td>
				  <td>Research Institute of the McGill University Health Centre</td>
				  <td>2020-05-23</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>MP-31-2019-2945<br>
					(Control # 237164)</td>
				  <td>Lessening Organ Dysfunction with Vitamin C (LOVIT)</td>
				  <td>Treatment: Vitamin C<br>
					(ascorbic acid)</td>
				  <td>Centre de recherche du centre hospitalier universitaire de Sherbrooke</td>
				  <td>2020-03-18</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT03680274">NCT03680274</a></td>
				</tr>
				<tr>
				  <td>MP-37-2021-6659<br>
					(Control #238811)</td>
				  <td>A Multi-Centre, Randomized, Blinded, Placebo Controlled Clinical Trial of the Safety and Effectiveness of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Children</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>Research Institute of the McGill University Health Centre</td>
				  <td>2020-05-04</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>MUHC_CAMOSTAT MESILATE<br>
					(Control #240313)</td>
				  <td>The impact of the Camostat Mesilate on COVID-19 Infection: A Randomized Controlled Phase II Clinical Trial</td>
				  <td>Treatment: CAMOSTAT</td>
				  <td>McGill University Health Centre</td>
				  <td>2020-07-02</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>NCT04405102<br>
					Control # 241148</td>
				  <td>A randomized trial on efficacy and safety of Ozanimod for the treatment of COVID-19 Patients requiring oxygen support - a pilot trial (COZI)</td>
				  <td>Treatment: Ozanimod</td>
				  <td>Institut universitaire de cardiologie et de pneumologie de Québec</td>
				  <td>2020-07-13</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/results/NCT04405102?view=results">NCT04405102</a></td>
				</tr>
				<tr>
				  <td>NTM-CTP-01<br>
					(Control # 236728)</td>
				  <td>An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents with Non-Tuberculous Mycobacteria</td>
				  <td>Treatment: nitric oxide</td>
				  <td>Dr. Jeremy Road</td>
				  <td>2020-03-19</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT03331445">NCT03331445</a></td>
				</tr>
				<tr>
				  <td>OZM-113 (Control # 238691)</td>
				  <td>Therapeutic-dose anti-coagulation for the treatment of hospitalized patients with COVID-19: the antthrombotic therapy to ameliorate complications of COVID01 (ATTACC) trial</td>
				  <td>Treatment: Innohep (Tinzaparin sodium) / Lovenox (enoxaparin sodium) / Fragmin (dalteparin sodium) / Heparin Sodium</td>
				  <td>University of Manitoba</td>
				  <td>2020-04-29</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>PDC01<br>
					(Control #242430)</td>
				  <td>A randomized, placebo-controlled, multicenter study to assess the safety &amp; efficacy of dapsone on the treatment of COVID-19 positive patients</td>
				  <td>Treatment: dapsone</td>
				  <td>Research Institute of the McGill University Health Centre</td>
				  <td>2020-08-20</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>PHRI.ACT.COVID19<br>
					(Control # 238157)</td>
				  <td>Anti-Coronavirus Therapies to Prevent Progression of COVID-19 (ACT), a Randomized Trial</td>
				  <td>Treatment: colchicine / acetylsalicylic acid / rivaroxaban / interferon beta-1b</td>
				  <td>Hamilton Health Sciences</td>
				  <td>2020-04-18</td>
				  <td><a href="https://www.clinicaltrials.gov/ct2/show/NCT04324463">NCT04324463</a></td>
				</tr>
				<tr>
				  <td>PREP2020<br>
					(Control #238396)</td>
				  <td>Pre-Exposure Prophylaxis fro SARS-Coronovirus-2: A Pragmatic Randomized Clinical Trial</td>
				  <td>Treatment: hydroxychloroquine</td>
				  <td>University of Manitoba</td>
				  <td>2020-04-21</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>PRO00100606<br>
					(Control # 240943)</td>
				  <td>Improving vitamin D status in the management of COVID-19</td>
				  <td>Treatment: Vitamin D</td>
				  <td>Governors of the University of Alberta</td>
				  <td>2020-07-27</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04385940">NCT04385940</a></td>
				</tr>
				<tr>
				  <td>Protocol 214094<br>
					(Control # 239770)</td>
				  <td>A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease</td>
				  <td>Treatment: GSK3196165 (Otilimab), monoclonal antibody</td>
				  <td>GlaxoSmithKline</td>
				  <td>2020-05-27</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>RAPID COVID COAG<br>
					(Control #238510)</td>
				  <td>Coagulopathy of COVID-19: A pragmatic randomized controlled trial of therapeutic anticoagulation versus standard care as a rapid response to the COVID-19 pandemic (RAPID COVID COAG)</td>
				  <td>Treatment: Fondaparinux / Innohep / Fragmin / Lovenox / Lovenox HP / Heparin sodium injection / Heparin sodium and 0.9% sodium chloride injection / Heparin sodium in 5% dextrose injection</td>
				  <td>Unity Health Toronto</td>
				  <td>2020-04-24</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>REB20-0713<br>
					(CTA Control # 239287)</td>
				  <td>A prospective, observational study to assess the efficacy and safety of adjunctive humanized monoclonal Interleukin 6 receptor antibody Tocilizumab (TCZ) therapy to standard of care for the reduction of hyperinflammation related mortality in SARS-Cov2 positive patients</td>
				  <td>Treatment: Actemra (Tocilizumab)</td>
				  <td>University of Calgary</td>
				  <td>2020-05-22</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>REMAP-CAP<br>
					X17-0199<br>
					(Control # 237719)</td>
				  <td>Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP):<br>
					PANDEMIC APPENDIX TO THE CORE PROTOCOL</td>
				  <td>Treatment: Lopinavir/Ritonavir,<br>
					Interferon beta-1a,<br>
					apo-Hydroxyquine<br>
					Heparin Sodium, Lovenox, Fragmin, Innohep,<br>
					Aphresis frozen plasma from recovered COVID-19 patients (Convalescent Plasma),<br>
					Kineret, Vitamin C</td>
				  <td>Unity Health Toronto</td>
				  <td>2020-04-01</td>
				  <td><a href="https://clinicaltrials.gov/show/NCT02735707">NCT02735707</a></td>
				</tr>
				<tr>
				  <td>SAIL-004<br>
					(Control # 237708)</td>
				  <td>Assessment of Investigational Medications adjunct to Clinical Standard of Care for Treatment of Moderate to Severe Coronavirus Disease (COVID-19)</td>
				  <td><br>
					Treatment: Baricitinib</td>
				  <td>Dr. Lisa Barrett</td>
				  <td>2020-04-14</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04321993?term=SAIL-004&amp;draw=2&amp;rank=1">NCT04321993</a></td>
				</tr>
				<tr>
				  <td>SAR153191<br>
					(Control # 237332)</td>
				  <td>An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19</td>
				  <td>Treatment: Kevzara<sup>®</sup>&nbsp;(sarilumab)</td>
				  <td>Sanofi-Aventis Canada Inc.</td>
				  <td>2020-03-24</td>
				  <td><a href="https://www.clinicaltrials.gov/ct2/show/record/NCT04315298">NCT04315298</a></td>
				</tr>
				<tr>
				  <td>U-DEPLOY<br>
					(OZUHN-001/ Sub-protocol # OZUHN-001-2)<br>
					(Control # 237848)</td>
				  <td>Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery</td>
				  <td>Treatment: Ruxolitinib, placenta derived decidual stromal cells (DSC)</td>
				  <td>University Health Network</td>
				  <td>2020-04-07</td>
				  <td><a href="https://clinicaltrials.gov/ct2/show/NCT04331665?term=ruxolitinib+and+covid+19&amp;draw=2&amp;rank=1">NCT04331665</a></td>
				</tr>
				<tr>
				  <td>VASCEPA -COVID-19 CARDIOLINK-9<br>
					(Control #239025)</td>
				  <td>An Investigation on the Effects of Icosapent Ethyl (Vascepa™) on Inflammatory Biomarkers in Individuals with COVID-19 Cardiolink-9</td>
				  <td>Treatment: icosapent (Vascepa™)</td>
				  <td>Canadian Medical and Surgical Knowledge Translation Research</td>
				  <td>2020-05-08</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>OHRI-HBOT-001<br>
					(Control #242108)</td>
				  <td>Multicentre Randomized Controlled Trial of Hyperbaric versus Normobaric oxygen therapy for COVID-19 Patients</td>
				  <td>Treatment: Oxygen</td>
				  <td>Ottawa Hospital Research Institute</td>
				  <td>2020-07-30</td>
				  <td>N/A</td>
				</tr>
				<tr>
				  <td>COV-01<br>
					Control # 242568<br>
					Authorized Under Clinical Trials Interim Order</td>
				  <td>Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients</td>
				  <td>Treatment: Taltz (Ixekizumab) / Otezla (Apremilast tablets)</td>
				  <td>Amgen Canada Inc.</td>
				  <td>2020-08-20</td>
				  <td>N/A</td>
				</tr>
			  </tbody>
			</table>
			
			
			
			</div>
		
		
  <div id="def-preFooter">
</div>
<!-- Write closure template -->
<script type="text/javascript">
	var defPreFooter = document.getElementById("def-preFooter");
	defPreFooter.outerHTML = wet.builder.preFooter({
		dateModified: "2020-03-13",
		showPostContent: true,
		showFeedback: true,
		showShare: true
	});
</script>
		</main>
		<div id="def-footer">

		</div>
		<!-- Write closure template -->
		<script type="text/javascript">
			var defFooter = document.getElementById("def-footer");
			defFooter.outerHTML = wet.builder.footer({
				showFooter: true,
				showFeatures: true
			});
		</script>
		<!-- Write closure template -->
				<script type="text/javascript">
			document.write(wet.builder.refFooter({
			}));
		</script>
		<script src="https://test.canada.ca/covid-19-guidance/proto/js/contact-link-swap.js"></script>
		<script src="https://test.canada.ca/covid-19-guidance/proto/js/alpha-banner.js"></script>
	</body>
</html>
